Plasma von Willebrand factor and soluble E-selectin levels in stable outpatients with systolic heart failure: The Frederiksberg heart failure study

International Journal of Cardiology

Volumn 119, Issue 1, 2007, Pages 80-82

  Chong, Aun Yeong ^a   Freestone, Bethan ^a   Lim, Hoong Sern ^a   Kistorp, Caroline ^b   Gustafsson, Finn ^c   Hildebrandt, Per ^b   Lip, Gregory Y H ^a  

^a CITY HOSPITAL   (United Kingdom)

^b FREDERIKSBERG HOSPITAL   (Denmark)

^c Rigshospitalet   (Denmark)

Author keywords

E selectin; Endothelial dysfunction; Von Willebrand factor

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXERCISE; FEMALE; HEART FAILURE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; WALKING;

AGED; BIOLOGICAL MARKERS; E-SELECTIN; ENDOTHELIUM, VASCULAR; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SOLUBILITY; SYSTOLE; VON WILLEBRAND FACTOR;

EID: 34249324428     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2006.07.085     Document Type: Article

References (7)

1. Chong A.Y., Blann A.D., and Lip G.Y. Assessment of endothelial damage and dysfunction: observations in relation to heart failure. QJM 96 (2003) 253-267
2. Nielsen O.W., Hilden J., McDonagh T., and Fischer H.J. Survival differences between heart failure in general practices and in hospitals. Heart 89 (2003) 1298-1302
3. Chong A.Y., Freestone B., Patel J., Lim H.S., Hughes E., Blann A.D., and Lip G.Y. Endothelial activation, dysfunction, and damage in congestive heart failure and the relation to brain natriuretic peptide and outcomes. Am J Cardiol 97(5) (2006 Mar 1) 671-675 (electronic publication 2006 Jan 10)
4. Galatius S., Gustafsson F., Nielsen P.H., Atar D., and Hildebrandt P.R. An integrated approach to diagnosis and therapeutic management of patients with systolic heart failure in the Copenhagen metropolitan area. Am Heart J 144 (2002) E2
5. Kistorp C., Galatius S., Gustafsson F., Faber J., Corell P., and Hildebrandt P. Prevalence and characteristics of diabetic patients in a chronic heart failure population. Int J Cardiol 100 (2005) 281-287
6. Chong A.Y., Blann A.D., Patel J., Freestone B., Hughes E., and Lip G.Y. Endothelial dysfunction and damage in congestive heart failure: relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide. Circulation 110 (2004) 1794-1798
7. Gibbs C.R., Blann A.D., Watson R.D., and Lip G.Y. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy. Circulation 103 (2001) 1746-1751